NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

I have just sent this e-mail to both Timothy Cloughsey and DI

To:
[e-mail]
,
Northwest Biotherapeutics

Fri, 10 Jun at 13:13

Good afternoon Timothy,
I would appreciate your assistance. I have just been reading a presentation attributed to you from CCO (clinical trial options) website. The title of the presentation and slides is: 'ExpressPoints: Applying Precision Medicine in Glioblastoma: New and Emerging Therapeutic Targets. The site lists you as "faculty who were involved in the production of these slides"

The slides state "Drug Development for Glioblastoma has many lengthy, costly (knowable?) failures and goes on to list these "failures" which includes DCVax,

Drug Development for Glioblastoma Has Many Lengthy, Costly (Knowable?) Failures



Later, the slides state "Late-stage failures with Immunotherapies in Glioblastoma" which again include 'Dendritic cell vaccine DCVax-L phase 3

Late-Stage Failures With Immunotherapies in Glioblastoma



As you will be aware, TLD for the phase 3 trial has been recently presented. The data presented shows that both endpoints have been met and were statistically significant and with excellent 'p' values. In light of these results, please could you address the obvious disparity as I am sure you will appreciate this could at the very least cause some confusion. I appreciate your assistance with this matter.

The website address containing the slide deck is ExpressPoints: Glioblastoma - Downloadable Slidesets - Precision Medicine in Glioblastoma

ExpressPoints: Glioblastoma - Downloadable Slidesets - Precision Medicin...
Expert-selected slides on new and emerging targeted therapies for glioblastoma, from Clinical Care Options (CCO).

https://www.clinicaloptions.com/oncology/programs/2022/glioblastoma-new-targets/downloadable-slidesets/expresspts